Update shared on 28 Oct 2025
Fair value Decreased 1.47%Analysts have slightly lowered their price target for Alexandria Real Estate Equities, setting it at $96.07 from the previous $97.50. This adjustment is based on updated projections for revenue growth and profit margins.
What's in the News
- Alexandria Real Estate Equities completed the repurchase of 2,648,569 shares, representing 1.53 percent, for $258.25 million under the buyback announced on December 9, 2024 (Key Developments).
- Reported impairment of real estate for Q3 2025 totaled $323.9 million, a significant increase from $5.7 million a year ago (Key Developments).
- The company updated its 2025 earnings guidance, lowering the midpoint of net (loss) income per share by $3.44 from $0.50 to $(2.94) (Key Developments).
- Announced the opening of Lilly Gateway Labs San Diego at One Alexandria Square Megacampus, in collaboration with Lilly Lilly and Company, expanding its innovation hub network for biotechnology companies (Key Developments).
- Hosted an Analyst/Investor Day (Key Developments).
Valuation Changes
- Consensus Analyst Price Target decreased slightly from $97.50 to $96.07.
- Discount Rate has risen modestly from 8.54 percent to 8.72 percent.
- Revenue Growth expectation increased from 0.70 percent to 1.06 percent.
- Net Profit Margin declined from 9.10 percent to 7.38 percent.
- Future P/E ratio has increased from 72.28x to 88.17x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.